TY - JOUR
T1 - Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors
T2 - A Pooled Analysis of 13 Case-Control Studies
AU - Rasmussen, Christina B
AU - Kjaer, Susanne K
AU - Albieri, Vanna
AU - Bandera, Elisa V
AU - Doherty, Jennifer A
AU - Høgdall, Estrid
AU - Webb, Penelope M
AU - Jordan, Susan J
AU - Rossing, Mary Anne
AU - Wicklund, Kristine G
AU - Goodman, Marc T
AU - Modugno, Francesmary
AU - Moysich, Kirsten B
AU - Ness, Roberta B
AU - Edwards, Robert P
AU - Schildkraut, Joellen M
AU - Berchuck, Andrew
AU - Olson, Sara H
AU - Kiemeney, Lambertus A
AU - Massuger, Leon F A G
AU - Narod, Steven A
AU - Phelan, Catherine M
AU - Anton-Culver, Hoda
AU - Ziogas, Argyrios
AU - Wu, Anna H
AU - Pearce, Celeste L
AU - Risch, Harvey A
AU - Jensen, Allan
AU - , on behalf of the Ovarian Cancer Association Consortium
N1 - © The Author 2016. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Inflammation has been implicated in ovarian carcinogenesis. However, studies investigating the association between pelvic inflammatory disease (PID) and ovarian cancer risk are few and inconsistent. We investigated the association between PID and the risk of epithelial ovarian cancer according to tumor behavior and histotype. We pooled data from 13 case-control studies, conducted between 1989 and 2009, from the Ovarian Cancer Association Consortium (OCAC), including 9,162 women with ovarian cancers, 2,354 women with borderline tumors, and 14,736 control participants. Study-specific odds ratios were estimated and subsequently combined into a pooled odds ratio using a random-effects model. A history of PID was associated with an increased risk of borderline tumors (pooled odds ratio (pOR) = 1.32, 95% confidence interval (CI): 1.10, 1.58). Women with at least 2 episodes of PID had a 2-fold increased risk of borderline tumors (pOR = 2.14, 95% CI: 1.08, 4.24). No association was observed between PID and ovarian cancer risk overall (pOR = 0.99, 95% CI: 0.83, 1.19); however, a statistically nonsignificantly increased risk of low-grade serous tumors (pOR = 1.48, 95% CI: 0.92, 2.38) was noted. In conclusion, PID was associated with an increased risk of borderline ovarian tumors, particularly among women who had had multiple episodes of PID. Although our results indicated a histotype-specific association with PID, the association of PID with ovarian cancer risk is still somewhat uncertain and requires further investigation.
AB - Inflammation has been implicated in ovarian carcinogenesis. However, studies investigating the association between pelvic inflammatory disease (PID) and ovarian cancer risk are few and inconsistent. We investigated the association between PID and the risk of epithelial ovarian cancer according to tumor behavior and histotype. We pooled data from 13 case-control studies, conducted between 1989 and 2009, from the Ovarian Cancer Association Consortium (OCAC), including 9,162 women with ovarian cancers, 2,354 women with borderline tumors, and 14,736 control participants. Study-specific odds ratios were estimated and subsequently combined into a pooled odds ratio using a random-effects model. A history of PID was associated with an increased risk of borderline tumors (pooled odds ratio (pOR) = 1.32, 95% confidence interval (CI): 1.10, 1.58). Women with at least 2 episodes of PID had a 2-fold increased risk of borderline tumors (pOR = 2.14, 95% CI: 1.08, 4.24). No association was observed between PID and ovarian cancer risk overall (pOR = 0.99, 95% CI: 0.83, 1.19); however, a statistically nonsignificantly increased risk of low-grade serous tumors (pOR = 1.48, 95% CI: 0.92, 2.38) was noted. In conclusion, PID was associated with an increased risk of borderline ovarian tumors, particularly among women who had had multiple episodes of PID. Although our results indicated a histotype-specific association with PID, the association of PID with ovarian cancer risk is still somewhat uncertain and requires further investigation.
KW - Case-Control Studies
KW - Comorbidity
KW - Contraceptives, Oral, Hormonal/administration & dosage
KW - Family Health
KW - Female
KW - Genetic Predisposition to Disease
KW - Hormone Replacement Therapy/adverse effects
KW - Humans
KW - Hysterectomy
KW - Neoplasms, Glandular and Epithelial/epidemiology
KW - Ovarian Neoplasms/epidemiology
KW - Pelvic Inflammatory Disease/complications
KW - Protective Factors
KW - Reproductive History
KW - Risk Factors
KW - Sterilization, Tubal
KW - Talc/adverse effects
U2 - 10.1093/aje/kww161
DO - 10.1093/aje/kww161
M3 - Review
C2 - 27941069
SN - 0002-9262
VL - 185
SP - 8
EP - 20
JO - American Journal of Epidemiology
JF - American Journal of Epidemiology
IS - 1
ER -
